| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 03/04/2003 | US6528082 Methods and pharmaceutical compositions employing desmethylselegiline to treat neoplastic diseases or conditions |
| 03/04/2003 | US6528080 Flowable, biocompatible, branched thermoplastic polymer used to form solid matrices such as implants and controlled-release, drug-formulations in a body |
| 03/04/2003 | US6528053 Reducing buildup in the blood and normalizing cholesterol and blood pressure, in a mammal. The compositions comprise Morinda citrifolia extract, red wine extract, prune extract, blueberry extract, pomegranate extract, apple extract, and an |
| 03/04/2003 | CA2400565A1 Biomodulated multiparticulate formulations |
| 03/01/2003 | WO2003000027A2 Blocking peptide for inflammatory cell secretion |
| 03/01/2003 | CA2452123A1 Blocking peptide for inflammatory cell secretion |
| 02/28/2003 | WO2002020009A1 Medicinal compositions |
| 02/28/2003 | WO2002017913A1 Medicinal compositions for preventing or treating heart failure |
| 02/28/2003 | CA2420951A1 Medicinal compositions |
| 02/28/2003 | CA2420844A1 Medicinal compositions for preventing or treating heart failure |
| 02/27/2003 | WO2003016917A2 Sodium channel regulators and modulators |
| 02/27/2003 | WO2003016563A2 Novel molecular target for neurotoxicity |
| 02/27/2003 | WO2003016549A2 Nucleic-acid associated proteins |
| 02/27/2003 | WO2003016506A2 Secreted proteins |
| 02/27/2003 | WO2003016499A2 Combinatorial methods for inducing cancer cell death |
| 02/27/2003 | WO2003016493A2 Transporters and ion channels |
| 02/27/2003 | WO2003016306A1 Hiv inhibiting pyrimidines derivatives |
| 02/27/2003 | WO2003015872A2 Intravaginal administration of an aromatase inhibitor for the treatment of oestrogen-dependent proliferative disorders |
| 02/27/2003 | WO2003015827A1 Anticancer drug-chitosan complex forming self-aggregates and preparation method thereof |
| 02/27/2003 | WO2003015820A1 GnRH AGONIST COMBINATION DRUGS |
| 02/27/2003 | WO2003015819A1 Complement pathway inhibitors binding to c5 and c5a without preventing formation of c5b |
| 02/27/2003 | WO2003015812A2 Beta-amyloid-analogue-t-cell epitop vaccine |
| 02/27/2003 | WO2003015807A1 Side effct-relieving agents and/or hypoglycemic effect enhancers for thiazolidine derivatives |
| 02/27/2003 | WO2003015799A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and chondroitin sulfate |
| 02/27/2003 | WO2003015798A1 Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue |
| 02/27/2003 | WO2003015797A1 Compositions for the treatment and prevention of pain and inflammation with a cyclooxygenase-2 selective inhibitor and glucosamine |
| 02/27/2003 | WO2003015795A1 Physiological method of improving vision |
| 02/27/2003 | WO2003015787A1 Use of bibn4096 in combination with other antimigraine drugs for the treatment of migraine |
| 02/27/2003 | WO2003015783A1 Method of treating alcoholism or alcohol abuse |
| 02/27/2003 | WO2003015778A1 Tyrosine kinase inhibitors |
| 02/27/2003 | WO2003015775A1 New dipeptidyl peptidase iv inhibitors and their uses for lowering blood pressure levels |
| 02/27/2003 | WO2003015770A1 Novel combination |
| 02/27/2003 | WO2003015769A1 Aminoalkyl-substituted aromatic bicyclic compounds, method for the production thereof and their use as medicaments |
| 02/27/2003 | WO2003015768A2 Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| 02/27/2003 | WO2003015763A1 Adjuvant chemotherapy for anaplastic gliomas |
| 02/27/2003 | WO2003015755A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 02/27/2003 | WO2003015748A2 Mucoadhesive erodible drug delivery device for controlled administration of pharmaceuticals and other active compounds |
| 02/27/2003 | WO2003015746A1 Nasal passage cleaning composition |
| 02/27/2003 | WO2003015707A2 Method for treating lung cancers |
| 02/27/2003 | WO2003015703A2 Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| 02/27/2003 | WO2003015699A2 Topical compositions and methods for treating pain |
| 02/27/2003 | WO2003015697A2 Interleukin-2 mutants with reduced toxicity |
| 02/27/2003 | WO2003015690A2 Method for treating primary insomnia |
| 02/27/2003 | WO2003015689A2 Pharmaceutical composition for the prophylaxis and/or treatment of virus diseases |
| 02/27/2003 | WO2003015667A1 Method and intra sclera implant for treatment of glaucoma and presbyopia |
| 02/27/2003 | WO2003015612A2 Materials and methods to promote repair of nerve tissue |
| 02/27/2003 | WO2003015608A2 Combination therapy for the treatment of cancer |
| 02/27/2003 | WO2003015521A1 Treatment of cancers by inhalation of stable platinum-containing formulations |
| 02/27/2003 | WO2003004098A8 Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent |
| 02/27/2003 | WO2003001881A3 Cell-based high-throughput screening methods |
| 02/27/2003 | WO2003000181A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 02/27/2003 | WO2002103000A3 Methods for modulating gap junctions |
| 02/27/2003 | WO2002100851A3 Thiophene derivatives as antiviral agents for flavivirus infection |
| 02/27/2003 | WO2002100348A3 Human monoclonal antibodies to epidermal growth factor receptor (egfr) |
| 02/27/2003 | WO2002098413A3 Pharmaceutical compositions comprising orlistat and fatty acids and/or salts thereof |
| 02/27/2003 | WO2002098354A3 Compositions and methods for inhibiting bone resorption |
| 02/27/2003 | WO2002098278A3 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 02/27/2003 | WO2002097046A3 B7 related protein-2 molecules and uses thereof |
| 02/27/2003 | WO2002096398A3 Medicament containing an effector of the glutathione metabolism together with $g(a)-lipoic acid for treating diabetes mellitus |
| 02/27/2003 | WO2002095704A9 Use of nf-kappa-b inhibitors to treat dry eye disorders |
| 02/27/2003 | WO2002094180A3 Pharmaceutically active isoindoline derivatives |
| 02/27/2003 | WO2002092129A3 Pharmaceutical combination comprising an anti-androgen and an oestrogen receptor beta agonist |
| 02/27/2003 | WO2002091992A3 Targeted delivery of drugs for the treatment of parasitic infections |
| 02/27/2003 | WO2002090325A3 Benzazepinone alpha v integrin receptor antagonists |
| 02/27/2003 | WO2002085301A3 Indole, azaindole and related heterocyclic amidopiperazine derivatives |
| 02/27/2003 | WO2002083064A3 A method of treating cancer |
| 02/27/2003 | WO2002074042A3 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 02/27/2003 | WO2002069903A3 Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases |
| 02/27/2003 | WO2002067869A3 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 02/27/2003 | WO2002066602A3 Detection of allergen-specific ige |
| 02/27/2003 | WO2002060388A3 Acyl sulfamides for treatment of obesity, diabetes and lipid disorders |
| 02/27/2003 | WO2002058717A3 Methods for treating rheumatoid arthritis using il-17 antagonists |
| 02/27/2003 | WO2002055093A3 Activated charcoal based composition and method for reducing hangover symptoms associated with the consumption of alcohol containing beverages |
| 02/27/2003 | WO2002055024A3 Therapeutic modulation of the tumor inflammatory response |
| 02/27/2003 | WO2002055022A3 Active metabolite of antifungal compound |
| 02/27/2003 | WO2002042436A3 Isolated human phosphatase proteins, nucleic acid molecules encoding them, and uses thereof |
| 02/27/2003 | WO2002032378A3 Fusion cells and cytokine compositions for treatment of disease |
| 02/27/2003 | WO2002028425A3 Methods for treating muscle injuries |
| 02/27/2003 | WO2002028379A3 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
| 02/27/2003 | WO2002022212A3 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 02/27/2003 | WO2002020768A3 Caveolin peptides and their use as therapeutics |
| 02/27/2003 | WO2002020767A3 G-csf analog compositions and methods |
| 02/27/2003 | WO2002016548A8 Novel g protein-coupled receptor |
| 02/27/2003 | WO2002011711A3 Formulations of mometasone and a bronchodilator for pulmonary administration |
| 02/27/2003 | WO2002008407A9 Gene-targeted non-human mammal with human fad presenilin mutation and generational offspring |
| 02/27/2003 | WO2002004605A3 Stimulation of cellular regeneration and differentiation in the inner ear |
| 02/27/2003 | WO2002002797A3 Regulation of human 11 beta-hydroxysteroid dehydrogenase 1-like enzyme |
| 02/27/2003 | WO2002001950A3 Transgenic mice containing targeted gene disruptions |
| 02/27/2003 | WO2001097860A3 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy |
| 02/27/2003 | WO2001092892A3 Methods to identify compounds that modulate rage |
| 02/27/2003 | WO2001085924A3 MODULATION OF η-SECRETASE ACTIVITY |
| 02/27/2003 | US20030041341 Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in DNA encoding 4E-BP1 |
| 02/27/2003 | US20030041339 Animal model for use in the treatment of vision defects |
| 02/27/2003 | US20030041337 Animal model for use in the diagnosis and treatment of diabetic phenotype |
| 02/27/2003 | US20030040607 Hematopoietic cell E-selection/L-selectin ligand polypeptides and methods of use thereof |
| 02/27/2003 | US20030040537 Treatment of migraine headache |
| 02/27/2003 | US20030040536 For therapy of disease states in mammals that are alleviated by a protein kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease |
| 02/27/2003 | US20030040534 For therapy of pulmonary hypertension, particularly primary pulmonary hypertension; benign prostatic hypertrophy; migraine; renal, glomerular or mesangial cell disorders; endotoxemia; ischemia; atherosclerosis; restenosis |
| 02/27/2003 | US20030040529 Combined agents for treatment of glaucoma |
| 02/27/2003 | US20030040526 Administering therapy regiment comprising at least one cycle of eflomithine, matulane and a nitrosourea for therapy of anaplastic glioma |